| Brett Lucas Brumbaugh, | |
|
400 Massasoit Ave Ste 113, East Providence, RI 02914-2040 | |
| (401) 490-7610 | |
| Not Available |
| Full Name | Brett Lucas Brumbaugh |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 400 Massasoit Ave Ste 113, East Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417671454 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT01077 (Rhode Island) | Primary |
| Provider Name | Carelink, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1386827889 PECOS PAC ID: 4688751522 Enrollment ID: O20170615000812 |
News Archive
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility.
A Danish study provides 10-year absolute risk estimates for dementia specific to age, sex and common variation in the APOE gene, which may help identify high-risk individuals who potentially could benefit from early targeted prevention.
Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today presented data that demonstrated patients treated for 10 and 15 years with COPAXONE® (glatiramer acetate injection) had significant reduction in disease severity. These data, generated from the longest continuous prospective study of any disease modifying therapy in relapsing remitting multiple sclerosis (RRMS), were presented today at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brett Lucas Brumbaugh, 400 Massasoit Ave Ste 113, East Providence, RI 02914-2040 Ph: (401) 490-7610 | Brett Lucas Brumbaugh, 400 Massasoit Ave Ste 113, East Providence, RI 02914-2040 Ph: (401) 490-7610 |
News Archive
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility.
A Danish study provides 10-year absolute risk estimates for dementia specific to age, sex and common variation in the APOE gene, which may help identify high-risk individuals who potentially could benefit from early targeted prevention.
Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today presented data that demonstrated patients treated for 10 and 15 years with COPAXONE® (glatiramer acetate injection) had significant reduction in disease severity. These data, generated from the longest continuous prospective study of any disease modifying therapy in relapsing remitting multiple sclerosis (RRMS), were presented today at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.
› Verified 4 days ago
Mr. Dino B Iacobo, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Evergreen Dr, East Providence, RI 02914 Phone: 401-438-3250 Fax: 401-438-4813 | |
Mrs. Karyssa Silva, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 30 Alexander Ave, East Providence, RI 02914 Phone: 401-438-7210 Fax: 401-435-4231 | |
Melissa Viens, OT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1 Kettle Point Ave, East Providence, RI 02914 Phone: 401-457-1580 Fax: 401-831-0500 | |
Mrs. Michelle Tedesco Choquette, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1 Kettle Point Ave, East Providence, RI 02914 Phone: 401-443-5000 | |
Mr. Erick Augustus Davis, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1275 S Broadway, East Providence, RI 02914 Phone: 401-438-7020 | |
Sarah Anne Thomas, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 400 Massasoit Ave, East Providence, RI 02914 Phone: 401-753-2210 | |
Rachel Joyce Caswell, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 400 Massasoit Ave Ste 113, East Providence, RI 02914 Phone: 401-490-7610 |